Veterinary Medicines

Colombovac PMV/POX

Authorised
  • Newcastle disease virus, strain La Sota, Inactivated
  • Pigeonpox virus, strain DD, Live
Download as PDF

Product identification

Medicine name:
Colombovac PMV/POX
Active substance:
  • Newcastle disease virus, strain La Sota, Inactivated
  • Pigeonpox virus, strain DD, Live
Target species:
  • Pigeon
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Newcastle disease virus, strain La Sota, Inactivated
    19.90
    antigen unit(s)
    /
    0.20
    millilitre(s)
  • Pigeonpox virus, strain DD, Live
    103.50
    tissue culture infective dose 50
    /
    0.20
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Pigeon
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01EH01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Portugal
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Portugal Lda.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Manufacturing & Research Spain S.L.
Responsible authority:
  • Directorate General For Food And Veterinary
Authorisation number:
  • 597/98 DGV
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Portuguese (PDF)
Published on: 15/06/2023
Updated on: 18/06/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."